Please assess the completion status of the following clinical trial:

Trial Title: Compare the Effectiveness Between Existing Treatment and New Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 5 years~* Symptomatic of malaria infection, i.e. history of fever or presence of fever \>37.5°c.~* microscopically confirmed asexual stages of Plasmodium falciparum ≥ 5/500 wbc (may be mixed with non- P.falciparum species) .~* Written informed consent given to participate in the trial.~* Participant or parent/guardian is willing and able to give informed consent for participation in the study.~* Participant or guardian is able to understand and participant can complete the study requirements~Exclusion Criteria:~* Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age unless menstruating).~* P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175 000/µL).~* Signs or symptoms indicative of severe malaria:~  * Impaired consciousness~ * Severe anaemia (Hct\<15%)~ * Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites.~ * Respiratory distress~ * Severe jaundice~* Patients who received any P. falciparum treatment within 2 months~* Known hypersensitivity to artemisinins - defined as history of erythroderma/ other severe cutaneous reaction, angioedema or anaphylaxis.~* History of epilepsy and other neurological disorders~* Splenectomy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DP (Type: EXPERIMENTAL): 2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
- MAS3 (Type: ACTIVE_COMPARATOR): 4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2

Based on this trial design, predict the completion outcome and termination type (if applicable).